Abnormal Histones Acetylation in Patients with Primary Sjögren's Syndrome

[1]  S. Little,et al.  Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease. , 2018, Acta biomaterialia.

[2]  Ted M. Lakowski,et al.  Increased Post-Translational Lysine Acetylation of Myelin Basic Protein Is Associated with Peak Neurological Disability in a Mouse Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis. , 2018, Journal of proteome research.

[3]  J. Pers,et al.  Epigenetic modifications in salivary glands from patients with Sjögren's syndrome affect cytokeratin 19 expression. , 2016, Bulletin du Groupement international pour la recherche scientifique en stomatologie & odontologie.

[4]  M. Bubb,et al.  Sjögren’s syndrome-associated microRNAs in CD14+ monocytes unveils targeted TGFβ signaling , 2016, Arthritis Research & Therapy.

[5]  J. Pers,et al.  Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration. , 2016, Journal of autoimmunity.

[6]  Li Wang,et al.  Autoantigen-targeting microRNAs in Sjögren’s syndrome , 2016, Clinical Rheumatology.

[7]  A. Syvänen,et al.  Genome-wide DNA methylation analysis in multiple tissues in primary Sjögren's syndrome reveals regulatory effects at interferon-induced genes , 2016, Annals of the rheumatic diseases.

[8]  Ping Zhang,et al.  miR-146a and miR-155 expression in PBMCs from patients with Sjögren's syndrome. , 2014, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[9]  Quan Du,et al.  MicroRNA Profiling in Chinese Patients with Primary Sjögren Syndrome Reveals Elevated miRNA-181a in Peripheral Blood Mononuclear Cells , 2014, The Journal of Rheumatology.

[10]  R. Zhong,et al.  Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis , 2014, Annals of the rheumatic diseases.

[11]  P. Coit,et al.  Genome‐Wide DNA Methylation Patterns in Naive CD4+ T Cells From Patients With Primary Sjögren's Syndrome , 2014, Arthritis & rheumatology.

[12]  W. Abbas,et al.  Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production , 2013, PloS one.

[13]  J. Pers,et al.  Epigenetics and Sjögren's syndrome. , 2012, Current pharmaceutical biotechnology.

[14]  M. Azuma,et al.  TNF-α inhibits aquaporin 5 expression in human salivary gland acinar cells via suppression of histone H4 acetylation , 2012, Journal of cellular and molecular medicine.

[15]  R. Grigg,et al.  Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. , 2012, Arthritis and rheumatism.

[16]  Kaleb M. Pauley,et al.  Altered miR‐146a expression in Sjögren's syndrome and its functional role in innate immunity , 2011, European journal of immunology.

[17]  A. Iwama,et al.  [Structure and function of MYST family histone acetyltransferases]. , 2011, [Rinsho ketsueki] The Japanese journal of clinical hematology.

[18]  J. Pers,et al.  The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome. , 2010, Arthritis and rheumatism.

[19]  Q. Lu,et al.  Abnormal histone modification patterns in lupus CD4+ T cells. , 2008, The Journal of rheumatology.

[20]  Wolfgang Fischle,et al.  Role of histone modifications in defining chromatin structure and function , 2008, Biological chemistry.

[21]  T. Fujimura,et al.  Mechanism of HDAC inhibitor FR235222-mediated IL-2 transcriptional repression in Jurkat cells. , 2007, International immunopharmacology.

[22]  A. El-Osta,et al.  Chromatin modifications and DNA double-strand breaks: the current state of play , 2007, Leukemia.

[23]  V. P. Collins,et al.  Differential expression of selected histone modifier genes in human solid cancers , 2006, BMC Genomics.

[24]  R. Cook,et al.  Modifications of H3 and H4 during Chromatin Replication, Nucleosome Assembly, and Histone Exchange* , 2006, Journal of Biological Chemistry.

[25]  Scott A. Busby,et al.  Resetting the epigenetic histone code in the MRL-lpr/lpr mouse model of lupus by histone deacetylase inhibition. , 2005, Journal of proteome research.

[26]  E. Kalkhoven,et al.  CBP and p300: HATs for different occasions. , 2004, Biochemical pharmacology.

[27]  J. Hamburger,et al.  Estimating the prevalence among Caucasian women of primary Sjögren's syndrome in two general practices in Birmingham, UK , 2004, Scandinavian journal of rheumatology.

[28]  R. Janknecht,et al.  The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. , 2002, Histology and histopathology.

[29]  L. W. Yuan,et al.  Histone acetylation by p300 is involved in CREB-mediated transcription on chromatin. , 2001, Biochimica et biophysica acta.

[30]  K. Imai,et al.  Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. , 2000 .

[31]  R. Evans,et al.  Nuclear Receptor Coactivator ACTR Is a Novel Histone Acetyltransferase and Forms a Multimeric Activation Complex with P/CAF and CBP/p300 , 1997, Cell.

[32]  X. Mariette,et al.  Corrigendum: Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements [Rheumatology, 54, (2015) (2230-2238)] DOI: 10.1093/rheumatology/kev200 , 2017 .

[33]  A. Vissink,et al.  Connective tissue diseases: Refining the classification criteria for primary Sjögren syndrome , 2016, Nature Reviews Rheumatology.